Zobrazeno 1 - 10 of 11 pro vyhledávání: '"Ryan Sugarman"'
1
Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
Autor: Daniel Lin, Hiep Nguyen, Ruchit Shah, Yao Qiao, John Hartman, Ryan Sugarman
Publikováno v: Gastric Cancer. 26:415-424
Background The phase 3 CheckMate 649 established superior overall survival of nivolumab in combination with chemotherapy (NIVO + chemo) compared with chemotherapy (chemo) alone as a first-line treatment for patients with Her2-negative advanced gastri
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::73644d8ca0f50c28bbfa2ed149b249d2
https://doi.org/10.1007/s10120-023-01372-7
Zobrazit plný text záznamu
3
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: Final results
Autor: Darren Cowzer, Abraham Jing-Ching Wu, Smita Sihag, Henry S. Walch, Bernard J. Park, David Randolph Jones, Ping Gu, Steven Brad Maron, Ryan Sugarman, Sree Bhavani Chalasani, Marina Shcherba, Marinela Capanu, Joanne F. Chou, Anton Nosov, Randy Yeh, Laura H. Tang, David H. Ilson, Yelena Y. Janjigian, Daniela Molena, Geoffrey Yuyat Ku
Publikováno v: Journal of Clinical Oncology. 40:4029-4029
4029 Background: Induction FOLFOX followed by PET-directed CRT prior to surgery demonstrated positive results in the CALGB 80803 study. We investigated the safety and efficacy of adding D, an anti-PD-L1 antibody, to PET-directed CRT. Methods: Patient
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::53451790d75fb63fc8d50c8c28e9f720
https://doi.org/10.1200/jco.2022.40.16_suppl.4029
Zobrazit plný text záznamu
4
A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC)
Autor: Ryan Sugarman, Marc Botteman, Nifasha Rusibamayila, Hiep Nguyen, Daniel Lin
Publikováno v: Journal of Clinical Oncology. 40:273-273
273 Background: In CheckMate 649 (CM 649), a randomized phase 3 trial of first-line treatment of advanced GC/GEJC/EAC, patients receiving nivolumab combined with chemotherapy (NIVO plus chemo) experienced superior overall survival (OS), progression-f
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7868e7bea3b5240f79691454438d09cf
https://doi.org/10.1200/jco.2022.40.4_suppl.273
Zobrazit plný text záznamu
5
PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer
Autor: Melissa Amy Lumish, Jenna L. Cohen, Zsofia Kinga Stadler, Jill A Weiss, Michelle F. Lamendola-Essel, Rona Yaeger, Neil Howard Segal, Imane H. El Dika, Leonard B. Saltz, Marina Shcherba, Ryan Sugarman, Avni Mukund Desai, Jesse Joshua Smith, Maria Widmar, Emmanouil Pappou, Philip Paty, Julio Garcia-Aguilar, Martin R. Weiser, Luis A. Diaz, Andrea Cercek
Publikováno v: Journal of Clinical Oncology. 40:16-16
16 Background: Total neoadjuvant therapy with induction chemotherapy and chemoradiation (chemoRT) is the standard treatment for locally advanced rectal adenocarcinomas. Mismatch repair deficient (dMMR) rectal tumors respond poorly to neoadjuvant chem
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::02c34e84e4dede8b153d7eb09c6cb5c5
https://doi.org/10.1200/jco.2022.40.4_suppl.016
Zobrazit plný text záznamu
6
Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC)
Autor: Ryan Sugarman, Sasikiran Nunna, Keith A. Betts, Xiaoyu Nie, Hiep Nguyen
Publikováno v: Journal of Clinical Oncology. 40:307-307
307 Background: Globally, GC/GEJ/EAC are one of the leading causes of cancer-related mortality. Systemic chemotherapy is the standard of care for advanced or metastatic GC/GEJC/EAC, but the prognosis is poor. In the CM 649 trial, nivolumab plus chemo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::63316fcdfe8dd039673f12b213d4b1b1
https://doi.org/10.1200/jco.2022.40.4_suppl.307
Zobrazit plný text záznamu
7
Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer
Autor: Ryan Sugarman, Dennis Plenker, David A. Tuveson, Muhammad Wasif Saif, Sandhya Sharma, Rajvi Patel
Publikováno v: Expert opinion on drug metabolismtoxicology. 15(7)
Introduction: Pancreatic cancer (PC) remains a disease with a dismal prognosis. Despite accounting for only 3% of cancer diagnosis, 7% of all cancer deaths in the United States are from PC. This is explained by many being diagnosed with late-stage di
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80a25d64d9cfc163ae536ef645c78738
https://pubmed.ncbi.nlm.nih.gov/31241371
Zobrazit plný text záznamu
8
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma
Autor: Valerie Johnson, Smita Sihag, Kendall Cowie, Abraham J. Wu, Jaclyn Norris, Geoffrey Y. Ku, Ping Gu, Yelena Y. Janjigian, David R. Jones, Lara Feder, Sree Bhavani Chalasani, Laura H. Tang, Daniela Molena, Bernard J. Park, Steven Brad Maron, Marina Shcherba, David H. Ilson, Ryan Sugarman
Publikováno v: Journal of Clinical Oncology. 39:226-226
394 Background: We previously presented safety data for the combination of D with carboplatin/paclitaxel (C/P) and RT for locally advanced esophageal cancer (J Clin Oncol 2018;36:172 [abstr]). Based on the positive results of the CALGB 80803 study (J
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b62098a1495992803a4209516f128b0
https://doi.org/10.1200/jco.2021.39.3_suppl.226
Zobrazit plný text záznamu
9
Large vessel stroke as initial presentation of thrombotic thrombocytopenic purpura
Autor: Ryan Sugarman, Andrea M Tufano, Johnson M Liu
Publikováno v: BMJ case reports. 2018
A 67-year-old right-handed woman presented with dysarthria, left upper extremity weakness and right-sided neglect of 3 hours duration. Imaging of the brain revealed acute right middle cerebral artery stroke; however, tissue plasminogen activator coul
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17ba98df7649a714f86d0376671540e2
https://pubmed.ncbi.nlm.nih.gov/29437728
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje